Ireland - English - HPRA (Health Products Regulatory Authority)

boehringer ingelheim limited - ipratropium bromide - pressurised inhalation soln - 20 mcg/dose - ipratropium bromide

Malta - English - Medicines Authority

boehringer ingelheim limited - ipratropium bromide - pressurised inhalation, solution - ipratropium bromide 20 µg - drugs for obstructive airway diseases

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - tiotropium bromide monohydrate (unii: l64sxo195n) (tiotropium - unii:0eb439235f) - tiotropium bromide monohydrate 18 ug - spiriva handihaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema. spiriva handihaler is indicated to reduce exacerbations in copd patients. spiriva handihaler is contraindicated in patients with a hypersensitivity to ipratropium or tiotropium.  in clinical trials and postmarketing experience with spiriva handihaler, immediate hypersensitivity reactions, including angioedema (including swelling of the lips, tongue, or throat), itching, or rash have been reported. teratogenic effects, pregnancy category c. there are no adequate and well-controlled studies in pregnant women.  spiriva handihaler should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. no evidence of structural alterations was observed in rats and rabbits at inhalation tiotropium doses of up to approximately 660 and 6

Malta - English - Medicines Authority

boehringer ingelheim international gmbh binger strasse 173, 55216 ingelheim am rhein, germany - ipratropium bromide - pressurised inhalation, solution - ipratropium bromide 20 µg - drugs for obstructive airway diseases

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

istituto de angeli s.r.l. loc. prulli - ipratropium bromide (ipratropium bromide monohydrate), fenoterol (fenoterol hydrobromide) - solution inhalation - 261mcg/ml+ 500mcg/ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

boehringer ingelheim pharma gmbh & co. kg - ipratropium bromide (ipratropium bromide monohydrate) - aerosol for inhalation, dosed - 20mcg/dose

New Zealand - English - Medsafe (Medicines Safety Authority)

boehringer ingelheim (nz) ltd - ipratropium bromide monohydrate 0.261 mg/ml equivalent to 0.25 mg/ml anhydrous ipratropium bromide - solution for inhalation - 0.25 mg/ml - active: ipratropium bromide monohydrate 0.261 mg/ml equivalent to 0.25 mg/ml anhydrous ipratropium bromide excipient: hydrochloric acid purified water sodium chloride

New Zealand - English - Medsafe (Medicines Safety Authority)

actavis new zealand limited - ipratropium bromide monohydrate 0.2088%{relative} equivalent to ipratropium 0.2% w/v; salbutamol sulfate 0.12%{relative} equivalent to 0.1% salbutamol base - solution for inhalation - 500µg/2.5mg per2.5ml - active: ipratropium bromide monohydrate 0.2088%{relative} equivalent to ipratropium 0.2% w/v salbutamol sulfate 0.12%{relative} equivalent to 0.1% salbutamol base excipient: hydrochloric acid sodium chloride water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ipratropium bromide monohydrate 0.3 g/l - nasal spray solution - 0.03 % - active: ipratropium bromide monohydrate 0.3 g/l excipient: benzalkonium chloride as 0.5ml/l of 50% solution purified water sodium chloride sodium edetate

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ipratropium bromide monohydrate 0.6 g/l - nasal spray solution - 0.06 % - active: ipratropium bromide monohydrate 0.6 g/l excipient: benzalkonium chloride as 0.5ml/l of 50% solution purified water sodium chloride sodium edetate